Cambrex Corp. (NYSE:CBM) insider Gregory Sargen sold 22,500 shares of the company’s stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $52.02, for a total transaction of $1,170,450.00. Following the transaction, the insider now owns 27,500 shares in the company, valued at approximately $1,430,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cambrex Corp. (NYSE:CBM) opened at 53.35 on Tuesday. Cambrex Corp. has a one year low of $29.50 and a one year high of $59.41. The company has a 50-day moving average of $43.77 and a 200 day moving average of $47.65. The firm has a market cap of $1.72 billion, a P/E ratio of 28.17 and a beta of 1.81.

Cambrex Corp. (NYSE:CBM) last released its earnings results on Friday, November 4th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.06. The company earned $99.90 million during the quarter, compared to the consensus estimate of $96.07 million. Cambrex Corp. had a return on equity of 24.11% and a net margin of 13.24%. Cambrex Corp.’s revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.40 EPS. Equities research analysts expect that Cambrex Corp. will post $2.70 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Cambrex Corp. (NYSE:CBM)

CBM has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Cambrex Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 27th. First Analysis upgraded shares of Cambrex Corp. from an “equal weight” rating to an “overweight” rating and set a $54.00 price target on the stock in a report on Monday, November 7th.

Several institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC bought a new position in shares of Cambrex Corp. during the second quarter valued at about $106,000. Acrospire Investment Management LLC boosted its position in shares of Cambrex Corp. by 149.0% in the second quarter. Acrospire Investment Management LLC now owns 2,674 shares of the company’s stock valued at $138,000 after buying an additional 1,600 shares during the last quarter. BlackRock Inc. boosted its position in shares of Cambrex Corp. by 38.6% in the second quarter. BlackRock Inc. now owns 2,855 shares of the company’s stock valued at $149,000 after buying an additional 795 shares during the last quarter. Intrust Bank NA bought a new position in shares of Cambrex Corp. during the second quarter valued at about $206,000. Finally, PineBridge Investments L.P. boosted its position in shares of Cambrex Corp. by 4.4% in the second quarter. PineBridge Investments L.P. now owns 4,056 shares of the company’s stock valued at $210,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 99.53% of the company’s stock.

Cambrex Corp. Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

5 Day Chart for NYSE:CBM

Receive News & Stock Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related stocks with our FREE daily email newsletter.